Home
Clinical Trials
Dose Ranging Study of ALX-017...

Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

Last Updated: 2019-10-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-11

Study Completion Date

2018-05-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to evaluate the anti-viral effect and safety of different doses of inhaled ALX-0171 in subjects hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection (RSV LRTI). The secondary objective is to evaluate the clinical activity, pharmacokinetic (PK) properties, pharmacodynamic (PD) effect and immunogenicity of different doses of inhaled ALX-0171.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171

NCT02309320

Respiratory Syncytial Virus Infection

COMPLETED PHASE1/PHASE2

Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

NCT03418571

Respiratory Syncytial Virus Lower Respiratory Tract Infection

TERMINATED PHASE2

Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness

NCT02148796

Asthma Wheezing

ACTIVE_NOT_RECRUITING PHASE2

An Investigational Drug Study to Treat Respiratory Symptoms Associated With Respiratory Syncytial Virus (RSV) Bronchiolitis (0476-272)

NCT00076973

Bronchiolitis

COMPLETED PHASE3

Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children

NCT00144846

Asthma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a Phase 2b, randomized, double-blind, placebo-controlled, international, multicenter dose-ranging study in infants and toddlers hospitalized for RSV LRTI. The study evaluated 3 dose levels of ALX-0171 in a sequential part (safety Cohorts 1-3) followed by a parallel part (Cohort 4).

An Independent Data Monitoring Committee (IDMC) was assigned to review study data and provide recommendations on proceeding to the next safety cohort and on which dose levels could be taken forward in the parallel part.

Three dose levels of ALX-0171 were evaluated:

* Dose 1: target dose of 3.0 mg/kg
* Dose 2: target dose of 6.0 mg/kg
* Dose 3: target dose of 9.0 mg/kg

The study drug was administered by inhalation once daily for 3 consecutive days along with standard of care treatment, which was determined by the Investigator (or his/her designee) according to institutional practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Syncytial Virus Lower Respiratory Tract Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ALX-0171 3.0 mg/kg

Inhalation of ALX-0171 3.0 mg/kg once daily for 3 consecutive days

Group Type EXPERIMENTAL

ALX-0171 3.0 mg/kg

Intervention Type BIOLOGICAL

ALX-0171 6.0 mg/kg

Inhalation of ALX-0171 6.0 mg/kg once daily for 3 consecutive days

Group Type EXPERIMENTAL

ALX-0171 6.0 mg/kg

Intervention Type BIOLOGICAL

ALX-0171 Dose 9.0mg/kg

Inhalation of ALX-0171 9.0 mg/kg once daily for 3 consecutive days

Group Type EXPERIMENTAL

ALX-0171 9.0 mg/kg

Intervention Type BIOLOGICAL

Placebo

Inhalation of Placebo once daily for 3 consecutive days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ALX-0171 3.0 mg/kg

Intervention Type BIOLOGICAL

ALX-0171 6.0 mg/kg

Intervention Type BIOLOGICAL

ALX-0171 9.0 mg/kg

Intervention Type BIOLOGICAL

Placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Matching Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female infant or young child aged 28 days to \< 2 years with gestational age ≥ 33 weeks at screening.
2. Subject weighed between ≥ 3.0 kg and \< 15.0 kg at screening.
3. Subject is otherwise healthy but was hospitalized for and clinically diagnosed with RSV LRTI (bronchiolitis or broncho-pneumonia), i.e., showing typical clinical signs and symptoms such as tachypnea, wheezing, cough, crackles, use of accessory muscles and/or nasal flaring.
4. Subject had a positive RSV diagnostic test at screening.
5. Subject was expected to have to stay in the hospital for at least 24 hours (according to the Investigator's judgment at screening).
6. Symptoms were likely related to RSV infection (i.e., the symptoms present needed to be probably linked to the current RSV infection according to Investigator's judgment) had appeared within 4 days of screening and were not yet improving at screening and randomization.
7. Subject fulfilled at least 2 of the following RSV disease severity criteria at screening and randomization:

* Inadequate oral feeding that required feeding support (i.e., nasogastric tube or intravenous \[i.v.\] line)
* Inadequate oxygen saturation defined as:

* Oxygen saturation (peripheral capillary oxygen saturation \[SpO2\]) ≤ 92% on room air or
* Requiring oxygen supplementation to maintain oxygen saturation \> 90% with documented pre-supplementation value ≤ 92%
* Signs of respiratory distress defined as:

* Respiratory rate ≥ 50 per minute in infants up to 12 months of age, and ≥ 40 per minute in children above 12 months and/or
* Moderate or marked respiratory muscle retractions
8. Normal psychomotor development.

Exclusion Criteria

1. Subject was known to have significant comorbidities including:

* Genetic disorders (e.g., trisomy 21, cystic fibrosis),
* Hemodynamically significant congenital heart disease (e.g., needing corrective therapy or inotropic support),
* Bronchopulmonary dysplasia,
* Any hereditary or acquired metabolic (bone) diseases,
* Hematologic or other malignancy.
2. Subject was known to be human immunodeficiency virus (HIV)-positive. If the subject was \< 6 months of age, a known HIV-positivity of the mother was also exclusionary.
3. Subject was known to be immunocompromised.
4. Subject had or was suspected to have an active, clinically relevant concurrent infection (e.g., bacterial pneumonia, urinary tract infection). Concurrent acute otitis media was not exclusionary.
5. Subject had significant oral and/or maxillofacial malformations that would prevent proper positioning of the face mask.
6. Subject received invasive mechanical ventilation or non-invasive respiratory support (i.e., continuous or bilevel positive airway pressure) in the 4 weeks prior to screening.
7. During the admission, the subject was initially hospitalized in an intensive care unit (ICU) setting and/or had received invasive mechanical ventilation or non-invasive respiratory support (i.e., continuous or bilevel positive airway pressure).
8. Subject was critically ill and/or was expected to require invasive mechanical ventilation, non invasive respiratory support (i.e., continuous or bilevel positive airway pressure), or High Flow oxygen therapy (HFOT) at levels not enabling nebulization therapy according to the Investigator's judgment. High Flow oxygen, with a maximum flow of 2 L/kg/min, was permitted under the following conditions:

* used as Standard of Care outside ICU setting
* could be removed for study drug administration (Note: oxygen flow at 2 L/min could be provided)

Minimum Eligible Age

28 Days

Maximum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers